Curated News
By: NewsRamp Editorial Staff
June 03, 2025

Cybin Secures U.S. Patent for Breakthrough Anxiety Treatment

Reddit View History of this news story on GitHub
Original Source

TLDR

  • Cybin Inc. secures U.S. patent 12,318,477 for CYB004, extending exclusivity until 2040 and positioning it as a leader in next-generation mental health therapies.
  • The patent covers novel intramuscular formulations of DMT for GAD treatment, with Phase 2 trials underway and completion expected by mid-2025.
  • Cybin's CYB004 program aims to revolutionize mental healthcare with rapid-acting, short-duration treatments, improving lives of those with generalized anxiety disorder.
  • Cybin now holds over 90 patents and 230 pending applications, showcasing its commitment to innovative psychedelic-based therapeutics for mental health.

Impact - Why it Matters

This news is pivotal as it highlights Cybin's advancement in developing innovative treatments for mental health conditions, particularly generalized anxiety disorder. The issuance of the U.S. patent not only validates the potential of CYB004 as a groundbreaking therapy but also strengthens Cybin's position in the competitive neuropsychiatry field. With mental health issues on the rise globally, Cybin's work could offer new hope to millions suffering from conditions that currently have limited treatment options. The company's extensive patent portfolio and ongoing research underscore its commitment to transforming mental healthcare through psychedelic-based therapeutics.

Summary

Cybin Inc., a leading clinical-stage neuropsychiatry company, has made a significant breakthrough in mental health therapy with the issuance of U.S. patent 12,318,477 for its CYB004 program. This patent covers novel intramuscular formulations of DMT and related compounds, aimed at treating generalized anxiety disorder (GAD), and extends the company's exclusivity through 2040. CEO Doug Drysdale emphasized the patent's role in validating CYB004's potential as a rapid-acting, short-duration treatment with patient-friendly delivery. Currently in Phase 2 trials, with completion expected by mid-2025, Cybin's CYB004 program is part of the company's broader mission to revolutionize mental healthcare. Cybin boasts an impressive intellectual property portfolio, with over 90 granted patents and more than 230 pending applications, underscoring its commitment to innovative psychedelic-based therapeutics. For more details, visit the Cybin press release.

Cybin's dedication to addressing the unmet needs in mental health treatment is supported by its global operations and partnerships with renowned scientists. The company is also developing CYB003, a deuterated psilocybin analog for major depressive disorder, alongside its CYB004 program. With headquarters in Canada and operations across the United States, the United Kingdom, the Netherlands, and Ireland, Cybin is at the forefront of psychedelic-based drug development. Investors and those interested in the latest updates can find more information in the company's newsroom at https://ibn.fm/CYBN.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Cybin Secures U.S. Patent for Breakthrough Anxiety Treatment

blockchain registration record for this content.